The decline in the reported number of new transmissions of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections across European Union (EU) and European Economic Area (EEA) countries has continued.
In this report, we provide an overview of the data reported by countries in the EU and EEA in 2023 to describe progress towards the 2025 interim targets for hepatitis elimination as outlined in the WHO European Region Action Plan 2022–2030.
In 2022, 23 273 cases of hepatitis C were reported in 29 EU/EEA countries. Excluding countries that only reported acute cases, 23 249 cases were notified, corresponding to a crude rate of 6.2 cases per 100 000 population.
Recent ECDC data show that despite progress in prevention and control efforts, the hepatitis B and hepatitis C viruses (HBV and HCV) continue to pose significant public health challenges in the European Union and European Economic Area (EU/EEA).
HelicsWin.Net (also referred to as HWN) is a software application developed for the manual entry of data of the ECDC HAI-Net surveillance of healthcare-associated infections (HAIs).
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
The food-borne infections listeriosis and shigatoxigenic Escherichia coli are increasing in the EU/EEA and were in 2022 at levels higher than before the COVID-19 pandemic.
For 2022, 29 European Union/European Economic Area (EU/EEA) countries reported 8 565 confirmed cases of Shiga toxin-producing Escherichia coli (STEC) infection.